Corporate VC Backing Influences Private M&A Step-Ups
This article was originally published in Start Up
New data show that including one or more corporate venture investors in a syndicate actually translates into a higher median step-up valuation.
You may also be interested in...
Based on a five-year analysis of the biopharma investments of SR One, Novartis Venture Funds, and Johnson & Johnson Development Corp., the "parent" entities of these CVC arms rarely, if ever, forge partnerships with their biotech portfolios.
Corporate venture capital groups have made an impact on life science investing in recent years, but when it comes to going public, the biotechs they back aren’t seeing an extra boost.
Plus news on recent financings by Regulus, Aragon, Antabio and Asceneuron.